

# SUSPECT ADVERSE REACTION REPORT

## I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) <b>PRIVACY</b>	1a. COUNTRY <b>COSTA RICA</b>	2. DATE OF BIRTH			2a. AGE	3. SEX	3a. WEIGHT	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION  <input type="checkbox"/> PATIENT DIED  <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY  <input type="checkbox"/> LIFE THREATENING <input type="checkbox"/> CONGENITAL ANOMALY <input checked="" type="checkbox"/> OTHER
		Day	Month	Year	Unk	Female	Unk	Day	Month	Year	
7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas) <b>Other Serious Criteria: Medically Significant</b> The patient ate something spoiled and became intoxicated [Food poisoning] The patient ate something spoiled, which caused stomach discomfort [Abdominal discomfort]  Case Description: Study ID: 828652-My Healthy Journey  Study description: Trial title: This is a 40 weeks digital patient support program with focus on exercise, motivation, nutrition & maintaining strategies (only for patients under Liraglutide 3.0 mg).  (Continued on Additional Information Page)											

## II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1 ) Saxenda (liraglutide 6 mg/mL) Solution for injection, 6 mg/mL		20. DID REACTION ABATE AFTER STOPPING DRUG?  <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
15. DAILY DOSE(S) #1 ) 1.8 mg, qd	16. ROUTE(S) OF ADMINISTRATION #1 ) Subcutaneous	
17. INDICATION(S) FOR USE #1 ) Weight loss (Weight control)		21. DID REACTION REAPPEAR AFTER REINTRODUCTION?  <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
18. THERAPY DATES(from/to) #1 ) JUN-2025 / Ongoing	19. THERAPY DURATION #1 ) Unknown	

## III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates      Type of History / Notes      Description Unknown		

## IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888		26. REMARKS Medically Confirmed: No
	24b. MFR CONTROL NO. <b>1506482</b>	25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.
24c. DATE RECEIVED BY MANUFACTURER <b>18-AUG-2025</b>	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER:	
DATE OF THIS REPORT <b>26-AUG-2025</b>	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	

---

**ADDITIONAL INFORMATION****7+13. DESCRIBE REACTION(S) continued**

Patient's height, weight and body mass index (BMI) were not reported.

This serious Solicited Report from COSTA RICA was reported by a Consumer as "The patient ate something spoiled and became intoxicated(Food poisoning)" beginning on 13-JUL-2025 , "The patient ate something spoiled, which caused stomach discomfort(Stomach discomfort)" beginning on 13-JUL-2025 and concerned a Female patient who was treated with Saxenda (liraglutide 6 mg/mL) from JUN-2025 and ongoing for "Weight loss",

Dosage Regimen of Saxenda: ??-JUN-2025 to Not Reported (Dosage Regimen Ongoing);

Medical history was not provided.

Treatment medications included - GRAVOL(DIMENHYDRINATE), BISMUTH SUBSALICYLATE., Nexium (esomeprazole)-(non-codable)

On 13-JUL-2025, The patient reports that the patient ate something spoiled, which caused stomach discomfort, and mentions that the patient became intoxicated (no further information provided).

The patient also indicates that the doctor agreed with the patient to remain on the dose of 1.8 mg and is currently at that dose, but does not specify how long they have been on that dose.

Batch Number of Saxenda has requested

Action taken to Saxenda was reported as No Change.

On 17-JUL-2025 the outcome for the event "The patient ate something spoiled and became intoxicated(Food poisoning)" was Recovered.

On 17-JUL-2025 the outcome for the event "The patient ate something spoiled, which caused stomach discomfort(Stomach discomfort)" was Recovered.

Reporter's causality (Saxenda) -

The patient ate something spoiled and became intoxicated(Food poisoning) : Unlikely

The patient ate something spoiled, which caused stomach discomfort(Stomach discomfort) : Unlikely

Company's causality (Saxenda) -

The patient ate something spoiled and became intoxicated(Food poisoning) : Unlikely

The patient ate something spoiled, which caused stomach discomfort(Stomach discomfort) : Possible

Company comment;

Food poisoning is assessed as an unlisted event; abdominal discomfort is assessed as listed event according to the Novo Nordisk company core data sheet (CCDS) for the Saxenda

A plausible explanation is that the food eaten was contaminated with pathogenic organisms that may have manifested as gastrointestinal discomfort.

Based on available information, the casual relationships between suspect product and adverse events are considered unlikely and related to other aetiologies.

This single case report is not considered to change the current knowledge of the safety profile of the product.